Sanofi Enters Multi-Billion Dollar Antibody Deals with Adagene and IGM
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)
Published: 31 Mar-2022
DOI: 10.3833/pdr.v2022.i3.2681 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi has been particularly busy on the deal making front in March 2022, entering into a number of key collaboration and licensing agreements in an attempt to bolster its therapeutic antibody pipeline...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS